Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
D
$14.00 mm in other securities, sold $14.00 mm, 2 investors
16 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
8-K
Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW
16 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
10 Aug 23
DEFA14A
Additional proxy soliciting materials
21 Jul 23
8-K
Other Events
21 Jul 23
EFFECT
Notice of effectiveness
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
7 Jul 23
S-3
Shelf registration
30 Jun 23
ARS
2022 FY
Annual report to shareholders
7 Jun 23
DEF 14A
Definitive proxy
7 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 23
8-K
Other Events
9 May 23
8-K
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
6 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
16 Mar 23
8-K
Other Events
13 Feb 23
8-K
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
19 Dec 22
S-8
Registration of securities for employees
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23
14 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
18 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug 22
DEFA14A
Additional proxy soliciting materials
21 Jul 22
8-K
Other Events
21 Jul 22
8-K
Onconova Therapeutics Announces Key Management Promotions
13 Jun 22
DEF 14A
Definitive proxy
25 May 22
10-Q
2022 Q1
Quarterly report
13 May 22
8-K
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
11 May 22
Latest ownership filings
3/A
Initial statement of insider ownership (amended)
12 Apr 24
3/A
Initial statement of insider ownership (amended)
11 Apr 24
SC 13D
Viriom, Inc.
8 Apr 24
4
Robert Redfield
3 Apr 24
4
Charles David Pauza
3 Apr 24
4
WERNER CAUTREELS
3 Apr 24
4
Nikolay Savchuk
3 Apr 24
4
Iain D. Dukes
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
3
Robert Redfield
3 Apr 24
3
Charles David Pauza
3 Apr 24
3
WERNER CAUTREELS
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
3
Nikolay Savchuk
3 Apr 24
3
Iain D. Dukes
3 Apr 24
4
Mark Patrick Guerin
15 Mar 24
4
Steven M Fruchtman
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Mark Patrick Guerin
9 Feb 24
4
Steven M Fruchtman
9 Feb 24
144
Notice of proposed sale of securities
8 Feb 24
4
Victor M Moyo
27 Oct 23
3
Victor M Moyo
27 Oct 23
4
Mary Teresa Shoemaker
14 Aug 23
4
JACK E STOVER
14 Aug 23
4
Peter Atadja
14 Aug 23
4
Trafford Clarke
14 Aug 23
4
VIREN MEHTA
14 Aug 23
4
JEROME GROOPMAN
14 Aug 23
4
JAMES J MARINO
14 Aug 23
4
Mark Patrick Guerin
4 Aug 23
4
Steven M Fruchtman
4 Aug 23
4
Mark Patrick Guerin
13 Jun 23
4
Mark Patrick Guerin
14 Mar 23
4
Steven M Fruchtman
14 Mar 23
4
Mark S. MD Gelder
14 Mar 23
4
Steven M Fruchtman
8 Feb 23
4
Mark S. MD Gelder
8 Feb 23